CA2979210A1 - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer

Info

Publication number
CA2979210A1
CA2979210A1 CA2979210A CA2979210A CA2979210A1 CA 2979210 A1 CA2979210 A1 CA 2979210A1 CA 2979210 A CA2979210 A CA 2979210A CA 2979210 A CA2979210 A CA 2979210A CA 2979210 A1 CA2979210 A1 CA 2979210A1
Authority
CA
Canada
Prior art keywords
cancer
antibody
cells
mab
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2979210A
Other languages
English (en)
French (fr)
Inventor
Kalipada Pahan
Original Assignee
Rush University Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rush University Medical Center filed Critical Rush University Medical Center
Publication of CA2979210A1 publication Critical patent/CA2979210A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2979210A 2015-03-11 2016-03-04 Compositions and methods for treating cancer Pending CA2979210A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131343P 2015-03-11 2015-03-11
US62/131,343 2015-03-11
PCT/US2016/020864 WO2016144743A1 (en) 2015-03-11 2016-03-04 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
CA2979210A1 true CA2979210A1 (en) 2016-09-15

Family

ID=56879779

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979210A Pending CA2979210A1 (en) 2015-03-11 2016-03-04 Compositions and methods for treating cancer

Country Status (5)

Country Link
US (1) US11279754B2 (https=)
EP (1) EP3268028B1 (https=)
JP (1) JP6871876B2 (https=)
CA (1) CA2979210A1 (https=)
WO (1) WO2016144743A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6871876B2 (ja) 2015-03-11 2021-05-19 ラッシュ ユニヴァーシティ メディカル センター がんを治療するための組成物と方法
US20230174636A1 (en) * 2020-05-12 2023-06-08 Rush University Medical Center Compositions and methods for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282204B2 (en) 2003-03-10 2007-10-16 Schering Corporation Uses of IL-23 agonists and antagonists; related reagents
MY157915A (en) * 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
WO2012159100A1 (en) * 2011-05-19 2012-11-22 Rush University Medical Center Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
JP6871876B2 (ja) 2015-03-11 2021-05-19 ラッシュ ユニヴァーシティ メディカル センター がんを治療するための組成物と方法

Also Published As

Publication number Publication date
WO2016144743A1 (en) 2016-09-15
EP3268028B1 (en) 2025-05-21
JP2018509469A (ja) 2018-04-05
US11279754B2 (en) 2022-03-22
EP3268028A4 (en) 2018-09-05
JP6871876B2 (ja) 2021-05-19
US20180194837A1 (en) 2018-07-12
EP3268028A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
US12318448B2 (en) Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cells
KR100847944B1 (ko) Ｃｄ40 항체 제제 및 방법
US9585957B2 (en) Adenosine receptor agonists and antagonists to modulate T cell responses
CN101873864A (zh) 用于诱发单核细胞免疫应答的重组细胞lag-3或其衍生物的应用
JP2023154065A (ja) 好酸球又はマスト細胞関連障害の治療
JP2022512161A (ja) 免疫療法のための組成物及び方法
JP6693873B2 (ja) Ｇｄ２陽性がんを処置するための製剤および方法
EP3268028B1 (en) Compositions and methods for treating cancer
CN102245205A (zh) 用于减少b-辅助性t细胞以治疗自身免疫疾病的方法
Jesus et al. Pediatric hereditary autoinflammatory syndromes
Casati et al. Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation
WO2020069439A1 (en) Pharmaceutical combination for the treatment of cancer
KR20220016104A (ko) 암 치료를 위한 프로카스파아제-3 활성화 및 면역요법
US20260069594A1 (en) Use of an agent capable of inhibiting the activation of mait cells for the treatment of rheumatoid arthritis
WO2017205779A2 (en) Compositions and methods for treating disorders related to inflammasome activity and il-1alpha expression
HK40074080A (en) Use of trl agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
Parker et al. Vitamin D Inhibits the Occurrence of
HK1172823A (en) Cd40 antibody formulation and methods
WO2016074580A1 (zh) 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210303

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240814

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250121

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250228

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250228

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250228

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250408

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250408

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250801

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251201